SPINK1 protein expression and prostate cancer progression
| Autor: | Lorelei A. Mucci, Whitney K. Hendrickson, Gregory L Judson, Edward C. Stack, Christopher S. Sweeney, Dyane Bailey, Andreas Pettersson, Meir J. Stampfer, Elizabeth Nuttall, Stephen P. Finn, Edward Giovannucci, Philip W. Kantoff, Neil E. Martin, Katja Fall, Rosina T. Lis, Michelangelo Fiorentino, Howard D. Sesso, Jennifer A. Sinnott, Lauren M. Kunz, Massimo Loda, Jennifer R. Rider, Richard Flavin, Christopher Fiore, Kathryn L. Penney |
|---|---|
| Přispěvatelé: | Flavin RJ, Pettersson A, Hendrickson WK, Fiorentino M, Finn SP, Kunz L, Judson G, Lis RT, Bailey D, Fiore C, Nuttall EJ, Martin NE, Stack EC, Penney KL, Rider JR, Sinnott JA, Sweeney CS, Sesso HD, Fall K, Giovannucci EL, Kantoff PW, Stampfer MJ, Loda M, Mucci LA |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
PCA3 Biochemical recurrence Male Cancer Research medicine.medical_specialty medicine.medical_treatment Adenocarcinoma TMPRSS2 Article Prosdtate cancer SPINK1 Prostate cancer Prostate Internal medicine Biomarkers Tumor Medicine PTEN Humans Aged Proportional Hazards Models Prostatectomy biology business.industry Cancer Prostatic Neoplasms Middle Aged medicine.disease Immunohistochemistry 3. Good health medicine.anatomical_structure Tissue Array Analysis Trypsin Inhibitor Kazal Pancreatic biology.protein Disease Progression Neoplasm Recurrence Local business Carrier Proteins |
| Zdroj: | Clinical cancer research : an official journal of the American Association for Cancer Research. 20(18) |
| ISSN: | 1557-3265 |
| Popis: | Purpose: SPINK1 overexpression has been described in prostate cancer and is linked with poor prognosis in many cancers. The objective of this study was to characterize the association between SPINK1 overexpression and prostate cancer–specific survival. Experimental Design: The study included 879 participants in the U.S. Physicians' Health Study and Health Professionals Follow-Up Study, diagnosed with prostate cancer (1983–2004) and treated by radical prostatectomy. Protein tumor expression of SPINK1 was evaluated by immunohistochemistry on tumor tissue microarrays. Results: Seventy-four of 879 (8%) prostate cancer tumors were SPINK1 positive. Immunohistochemical data were available for PTEN, p-Akt, pS6, stathmin, androgen receptor (AR), and ERG (as a measure of the TMPRSS2:ERG translocation). Compared with SPINK1-negative tumors, SPINK1-positive tumors showed higher PTEN and stathmin expression, and lower expression of AR (P < 0.01). SPINK1 overexpression was seen in 47 of 427 (11%) ERG-negative samples and in 19 of 427 (4%) ERG-positive cases (P = 0.0003). We found no significant associations between SPINK1 status and Gleason grade or tumor stage. There was no association between SPINK1 expression and biochemical recurrence (P = 0.56). Moreover, there was no association between SPINK1 expression and prostate cancer mortality (there were 75 lethal cases of prostate cancer during a mean of 13.5 years follow-up; HR = 0.71; 95% confidence interval, 0.29–1.76). Conclusions: Our results suggest that SPINK1 protein expression may not be a predictor of recurrence or lethal prostate cancer amongst men treated by radical prostatectomy. SPINK1 and ERG protein expression do not seem to be entirely mutually exclusive, as some previous studies have suggested. Clin Cancer Res; 20(18); 4904–11. ©2014 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|